Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine and Perampanel in Treatment Resistant Depression
NCT05915013Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Sep 2023
- Primary completion
- Dec 2032
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in treatment-resistant depression (TRD) comparing ketamine plus perampanel with ketamine plus placebo (2 arms). Primary endpoints: Prefrontal functional connectivity at 2.5 hours and Cerebral metabolic rate of oxygen at 2.5 hours. Started Sep 2023; status: recruiting.
02
Drugs
ketamineperampanel
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05915013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05915013.